Psychedelic Science Review Editor Barb Bauer conducts a review of some landmark studies.
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
Researchers are uncovering reasons to think there’s more to DMT than just hallucinations.
This phenomenon plays an important role in psychedelic drug research and development.
The primary active compound in this plant is more potent than LSD.
This structural analog of DMT is an understudied compound presenting new options for psychedelic drug development.
Using psychedelics to treat chronic pain is understudied yet full of potential.
“In the pharmaceutical drug development community, this is what you dream about.”
Three doses of fluoxetine were needed to elicit the effects of one dose of noribogaine.
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.